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Abstract
Purpose The established treatment for small-cell lung
cancer has been a cisplatin–etoposide combination, as the
most effective chemotherapy regimen. Paclitaxel has also
been used in combination with cisplatin and etoposide but
this has been unacceptable due to the toxicity. This toxicity
could be attributed to the three consequent days of treat-
ment with etoposide plus the doses of each of the three
drugs. Our objectives were to determine an equal or longer
survival and lower toxicity by administering all 3 drugs
with low dosage on day one, compared to the established
guideline of 3-day administration.
Methods We tested the aforementioned three-drug com-
bination and avoided the toxicity in the majority of patients
by administering all 3 drugs on day one. Fifty-one patients
(50 evaluable) were recruited from 4 oncology clinics. All
patients had histologically or cytologically confirmed
small-cell lung cancer with limited and extensive disease in
40 and 60 % of the patients, respectively. The treatment
was: cisplatin 75 mg/m2, etoposide 120 mg/m2 (maximum
200 mg), and paclitaxel 135 mg/m2. The agents were
administered on day one and repeated every 3 weeks for 6
cycles.
Results The median survival was 15 months (95 % CI
13.6–16.4) (mean 16 months). Forty-five (90 %) patients
achieved a response: 20 (40 %) patients, a complete
response and 25 (50 %), a partial response. Adverse reac-
tions included grade 3 and 4 neutropenia in 12 and 2 % of
the patients, respectively. Other side effects were of very
low toxicity.
Conclusion The 1-day, three-agent (cisplatin–etoposide–
paclitaxel) treatment of small-cell lung cancer is beneficial
with respect to response rate and survival, and the toxicity
is low and well-tolerated.
Keywords Small-cell lung cancer  Three-drug
combination treatment  Three drugs small-cell lung cancer
Introduction
According to the chemotherapy guidelines, chemotherapy
treatment of small-cell lung cancer (SCLC) has, for many
years now, been the combination of cisplatin and etopo-
side [1]. Carboplatin has been substituted for cisplatin in
order to avoid the nephrotoxicity of the latter, but no
statistically significant difference was determined with
respect to survival [2]. Many other cytotoxic combina-
tions have been tested, without achieving better results
[3–9]. SCLC is not an uncommon malignancy and it is
detected in nearly 20 % of patients with lung carcinomas
[10]. SCLC is a malignancy sensitive to chemotherapy
and radiation therapy as the great majority of treated
patients achieve complete and partial responses [11, 12].
Despite the initial responses in a high percentage of
patients, disease recurrence is very common in about
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85–90 %. The cytotoxic agents used, apart from cisplatin
and etoposide, have been alkylating agents, anthracy-
clines, vinca alkaloids, taxanes, and camptothecins [3, 7,
13]. The 5-year survival rate has been reported to be
relevant to only a small number of patients. Etoposide
became an eligible agent for SCLC treatment as it has
been administered in trials as monotherapy, given for
several consecutive days and showing an 81–87 %
response rate and a median survival of 7.1–9.4 months
[11]. Chemotherapy has been shown to be more effective
in limited disease as the median, and overall survival has
been statistically significantly longer than in extensive
disease [14]. Similar studies have been performed with
approximately the same results [15, 16].
Future studies to find a substitute for the standard
treatment of cisplatin–etoposide are probably needed. One
may consider that the cisplatin–etoposide combination
comes with two problems in clinical practice: the first is the
toxicity which is quite high, particularly with high dosage
cisplatin [7, 16], and second, the 3-day duration of etopo-
side administration.
In the present trial, the three agents, cisplatin, etoposide,
and paclitaxel, which are already considered to be the most
effective, are all given on 1 day every 3 weeks. The
objectives of the present study were to determine an equal
or longer survival and lower toxicity compared to the
established guideline of 3-day drug administration.
Patients and methods
Eligibility criteria
The eligibility criteria included patients with limited and
extensive small-cell lung cancer disease, histologically or
cytologically confirmed, a performance status (PS) of B2
(ECOG scale) and a life expectancy of at least 12 weeks.
Patients were required to have adequate bone marrow
function (absolute neutrophil count C1.5 9 109/l, platelet
count C100 9 109/l and hemoglobin C100 g/l), adequate
liver function (total bilirubin B1.5 times the upper nor-
mal limit, AST and/or ALT B3 times the upper normal
limit), and a creatinine clearance rate of C60 ml/min.
Patients with asymptomatic brain metastases were eligi-
ble. Patients with cardiac arrhythmias, heart failure, AV
block or acute myocardial infarction within 4 months
before study entry, as well as those with concurrent or
previous malignancies (except adequately treated squa-
mous-cell carcinoma of the skin) were excluded. The
lower age limit for enrollment was 18 years. All patients
gave their written informed consent and the protocol was
approved by the hospitals and the local ethics regulatory
bodies.
Study design and sample size
This study was designed as a multicenter Phase II trial with
four participating hospitals. The study was powered at
80 % to determine the response rate and survival. The
sample size was initially planned to include 20 patients
with an increased number of patients if 5 %, with regard to
median survival, and response rate was not reached. If
there had been no responses, the treatment would have
been stopped. The evaluation was performed centrally and
stratified by three prognostic variables: disease stage
(limited vs. extensive disease) a PS of 0–2 and the inves-
tigational site.
Treatment plan
All patients were designated to receive six cycles of the
three anticancer agents: cisplatin (CDDP), etoposide and
paclitaxel (PCT). The doses of all agents were lower than
the dosage which would have been given if only two of the
agents had been combined: CDDP 75 mg/m2 for 2 h plus
1 l of normal saline hydration, etoposide 120 mg/m2 (the
usual daily dose) and not higher than 200 mg administered
for 30 min and PCT 135 mg/m2 for a 3-h infusion. The
dose reduction of all 3 agents had to be done because the
3-drug administration at a higher dose would have
increased the toxicity. The drugs were administered the
first day only, and the courses were repeated every 21 days
(3 weeks). Treatment was performed at an outpatient clinic.
Patients who responded to the treatment continued up to
the end of six cycles. Hemopoietic growth factor was not
applied prophylactically, but only in cases of grade 3 and 4
neutropenia.
Baseline and treatment assessment and evaluation
Before study entry, all patients underwent the following
evaluations: medical history, physical examination, tumor
measurement or evaluation, ECOG performance status,
ECG, full blood count, liver and renal function test and
urinolysis. Staging was determined by chest and abdominal
computed tomography, bone scan and occasionally mag-
netic resonance imaging. Blood count, blood urea, and
serum creatinine were measured before each treatment
administration and 7 days after each course. Radiologic
tests were conducted after the current course of treatment if
the clinical signs were indicative of disease progression, or
at the end of six courses. For the assessment of response,
we used imaging-based evaluation. A complete response
(CR) was defined as the disappearance of all measurable
disease confirmed at 4 weeks at the earliest; partial
response (PR), a 30 % decrease in tumor burden, also
confirmed at 4 weeks at the earliest. In stable disease (SD),
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neither PR nor progressive disease (PD) criteria were met;
PD, a 20 % increase in tumor burden and no CR, PR or SD
before increased disease. Response data were based on the
response evaluation criteria in solid tumors (RECIST) [17].
A two-step deterioration in performance status, a [10 %
loss in pre-treatment weight or increasing symptoms did
not, by themselves, constitute progression of the disease;
however, the appearance of these complaints was followed
by a new evaluation of the extent of the disease. All
responses had to be maintained for at least 4 weeks and to
be confirmed by two independent radiologists and three
experienced oncologists.
Statistical design
The study was designed as a group sequential clinical trial
and an intent-to-treat analysis. An interim analysis based
on the O’Brien/Fleming boundary values was performed
when 50 % of the end points had been reached. Stratifi-
cation factors comprised limited and extensive disease.
Pearson’s x2 test (or Fisher’s exact test, when appropriate)
was used for the comparisons of categorical variables.
Time-to-event analysis was performed and survival distri-
bution was estimated by the Kaplan–Meier curve. All
reported p values are two-sided. A p \ 0.05 was consid-
ered significant. The end points were median and overall
survival, response rate, and toxicity.
Results
From January 2008 till July 2011, 51 patients were enrolled
in the study. One patient was excluded, having stopped
treatment after the first course. Fifty patients received
chemotherapy and nearly all completed the planned cour-
ses and were evaluable. The patients’ demographic and
disease characteristics at baseline are shown in Table 1.
There were 39 males and 11 females, 20 patients with
limited disease and 30 with extensive. The median age was
64 years (range 45–83 years).
Compliance with treatment
The total number of chemotherapy cycles was 278 and
the median number of cycles was 5. The median interval
for each patient was 21 days. No delay of treatment was
necessary apart from 2 patients who had myelotoxicity, in
which cases the delay was 1 week. There was no reduc-
tion in treatment. Growth factor was given to only 2
patients. Forty-six (92 %) of the patients completed the
treatment.
Response to treatment
Responses were analyzed on an intent-to-treat basis.
Responses were observed in 45 patients (90 %), 20 with a
complete response (40 %) and 25 with a partial response
(50 %), stable disease in 3 patients (6 %) and disease
progression in 2 patients (4 %), as shown in Table 2.
Complete responses were observed in patients with limited
and extensive disease.
Survival
The median survival was 15 months (95 % confidence
interval 13.6–16.4) (mean 16 months). All of the patients
with limited and extensive disease were included. It is
important to note that in the survival of over a year, 60 %
of the patients had had extensive disease. Fourteen/20
(70 %) patients with limited disease had a survival rate of
15 months or longer, whereas 6/30 (20 %) patients with
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extensive disease had a survival rate of 15 months or
longer. The Kaplan–Meier survival curve is shown in
Fig. 1.
Toxicity
Serious adverse reactions were not common. Alopecia
occurred in 68 % of the patients. Myelotoxicity, and in
particular neutropenia of different grades, was the most
common. Serious grade 3 and 4 neutropenia occurred in 12
and 2 % of the patients, respectively; for grade 1 and 2, it
was 14 and 28 %, respectively, which did not create a need
for treatment delay. Grade 3 thrombocytopenia was expe-
rienced by 6 % of the patients and grades 1 and 2, 18 %;
there was no grade 4 thrombocytopenia. Neuropathy in
total was experienced by 20 % of the patients. The data
related to adverse reactions are shown in Table 3.
Second-line treatment
Patients with recurrence after a complete response or dis-
ease progression underwent second-line chemotherapy
with irinotecan monotherapy or in combination with car-
boplatin (or cisplatin). Twenty-three patients were treated:
5 had a complete response; 6 had a partial response; 4 had
stable disease; and 8 had disease progression.
All patients with limited disease underwent radiation
therapy at the primary site (the dose was 4,000 cGy). Brain
irradiation (the dose was 3,000 cGy) was performed when
metastases appeared.
Discussion
In trying to improve the results of chemotherapy in SCLC,
quite a number of studies have been done. The combination
of cisplatin with etoposide has remained in the chemo-
therapy guidelines. Cyclophosphamide with doxorubicin
and vincristine showed no difference in effectiveness in
SCLC [15]. This three-drug combination only increased the
toxicity. The combination of cisplatin–etoposide–ifosfa-
mide did not improve the effectiveness but the toxicity was
increased [9, 18]. The fact that there is a need to increase
effectiveness and the survival rate, as well as to reduce
tumor recurrence, is a current reality for oncologists.
Although there have been numerous attempts to improve
the treatment, the optimal duration of chemotherapy in
order to achieve an amelioration has not been defined.
Evidence available from reported randomized trials with
respect to maintenance chemotherapy showed no prolon-
gation of survival [19–22]. Another attempt to improve the
survival rate without reducing the quality of life in SCLC
was made by increasing the dose-intensity of chemother-
apy with granulocyte colony-stimulating factor support
[23]. Another trial used the dose-intensity of a four-drug
chemotherapy regimen with or without recombinant human
granulocyte–macrophage colony-stimulating factor in
extensive-stage small-cell lung cancer [24]. The efforts of
the aforementioned trials did not become part of clinical
practice because no further effectiveness was reported. In
our trial, three agents were used in combination. With
respect to the chemotherapy guidelines, 2 of the 3 drugs
were cisplatin and etoposide and the third agent was pac-
litaxel. These 3 drugs have been used in the other trials.
One of these was in a randomized trial, while in another
study, the 3 drugs were administered in a Phase I study [25,
26]. The main outcome of these trials was toxicity due to
the drug dosage and to the three-day treatment of etopo-
side. The comparison of cisplatin–etoposide versus cis-
platin–paclitaxel has also been tested without producing
different results in effectiveness and survival [27].























Fig. 1 Kaplan–Meier survival curve. Median survival time 15 months,
















Neutropenia 7 (14) 14 (28) 6 (12) 1 (2) 28 (56)
Thrombocytopenia 8 (16) 1 (2) 3 (6) – 12 (24)
Anemia 3 (6) 5 (10) 2 (4) – 10 (20)
Neuropathy 3 (6) 6 (12) 1 (2) – 10 (20)
Mucositis 1 (2) 1 (2) – – 2 (4)
Nephrotoxicity 1 (2) – – – 1 (2)
Asthenia 4 (8) 4 (8) – – 8 (16)
Anorexia 2 (4) – – – 2 (4)
Nausea/vomiting 1 (2) 2 (4) – – 3 (6)
Allergy 1 (2) – – – 1 (2)
Alopecia – – 34 (68) – 34 (68)
Cardiotoxicity – – – – –
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In the present Phase II trial, the objective was to increase
the survival rate and reduce the toxicity, with the use of the
three agents cisplatin, etoposide, and paclitaxel. Whenever
three agents are combined in cancer clinical practice, one
has to be wary of the possible adverse reactions. By
reducing the doses of the three drugs and administering all
three on day one, and repeating the treatment after 3 weeks,
the toxicity was well-tolerated, the effectiveness was high,
and the survival rate was one of longest reported in SCLC
treatment. It is also important to take into account, the
better quality of life of the patients in receiving the drug
administration once every 3 weeks.
Conclusion
In the present trial, the three cytotoxic agents, cisplatin,
etoposide, and paclitaxel, were administered on day one,
every 3 weeks, thus avoiding the three-day treatment and
reducing the established drug dosage. The effectiveness
and survival were quite good and the toxicity very low and
very well-tolerated.
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